Quick answer
What should a semaglutide GLP-1 receptor binding experiment measure, and how is affinity calculated? Binding assays report an IC50 from a competition curve, which converts to an inhibition constant with the Cheng-Prusoff relationship, Ki = IC50 ÷ (1 + [L] ÷ Kd), where [L] is the labeled-ligand concentration and Kd its dissociation constant. The discovery paper reported semaglutide's receptor affinity as 0.38 ± 0.06 nM, about three-fold lower than liraglutide's, with higher albumin affinity. Structural papers show that semaglutide engages the receptor much as GLP-1 does but with different motions, and that N-terminal changes can bias signaling. This article walks through the assay arithmetic, controls and interpretation limits. V8 Peptides supplies a 10 mg lyophilized semaglutide vial, for laboratory research use only.
"Receptor binding" can mean a competition assay, a kinetic measurement, a cell-based signaling readout or a cryo-EM structure, and these answer different questions. This article separates them, shows the standard conversions with worked formula-only examples (numbers are illustrations, not data from any paper), and summarizes what the published semaglutide abstracts say about each. For mechanism background see incretin receptors explained and the semaglutide research guide. For laboratory research use only.
Four things "binding" can mean
| Experiment | What it yields | What it cannot tell you |
|---|---|---|
| Competition binding | IC50, converted to Ki | Whether the ligand activates the receptor |
| Saturation binding | Kd and Bmax of a labeled ligand | Affinity of unlabeled competitors |
| Functional signaling (cAMP, β-arrestin) | EC50 and efficacy, possibly bias | Direct affinity (response amplification distorts potency) |
| Structural (cryo-EM) | Atomic model of the complex | Kinetics or population behavior outside the captured state |
The semaglutide literature contains all four. The discovery paper reports an affinity value (0.38 ± 0.06 nM) (reference 1). Two structural papers describe semaglutide- and taspoglutide-bound GLP-1R–Gs complexes and N-terminally modified agonists respectively (references 2 and 3). A backbone-modification study links ligand structure to prolonged signaling (reference 4).
Competition binding and the Cheng-Prusoff conversion
In a competition assay, increasing concentrations of unlabeled semaglutide displace a fixed concentration of labeled ligand from receptor-containing membranes or cells. The midpoint of the displacement curve is the IC50. Because the IC50 depends on how much labeled ligand was used, the classic Cheng-Prusoff relationship converts it to an inhibition constant that is independent of the assay's tracer concentration (reference 5):
Ki = IC50 ÷ (1 + [L] ÷ Kd)
Worked illustration, with invented numbers: if the observed IC50 is 2.0 nM, the tracer concentration [L] is 0.5 nM and the tracer's Kd is 0.5 nM, then Ki = 2.0 ÷ (1 + 1) = 1.0 nM. If the tracer were present at four times the Kd, the same IC50 would convert to Ki = 2.0 ÷ 5 = 0.4 nM. The relationship assumes competitive binding at one site, equilibrium, and negligible ligand depletion; depletion is a real risk with a hydrophobic peptide that sticks to plasticware, so concentrations should be verified, not assumed.
| Assumption of Cheng-Prusoff | How a semaglutide assay can violate it | Check |
|---|---|---|
| Equilibrium reached | Slow dissociation of a long-acting analog | Time course at two incubation times |
| No ligand depletion | Adsorption of acylated peptide to plastic | Low-binding plates; measure concentration |
| Single competitive site | Allosteric or multiple-state binding | Hill slope near 1 |
| Tracer Kd known | Kd measured under different buffer conditions | Saturation experiment in the same buffer |
Why the albumin term matters
Semaglutide's fatty diacid binds albumin, and the discovery paper emphasized that the optimal compound combined high albumin affinity with GLP-1 receptor potency (reference 1). The consequence for any assay is that the measured apparent affinity depends on the albumin present in the buffer: a molecule bound to albumin is not free to bind receptor. The structure-activity literature on fatty-acid derivatives found that the spacer between peptide and fatty acid mostly governs potency while the fatty acid contributes to both potency and protraction (reference 6). In practice, when two papers report different affinities for the same compound, the first question is whether albumin was present and at what concentration. A laboratory should record buffer composition completely and, where the question concerns the free compound, run parallel conditions with and without albumin. This is an experimental-design recommendation; the cited abstracts do not give assay buffer details, so none are assumed here.
The free fraction relationship is simple: if the compound is bound in a fast equilibrium to albumin with dissociation constant Kd,alb, the free concentration is roughly total ÷ (1 + [albumin] ÷ Kd,alb) when albumin is in excess. Plugging in measured values converts nominal to effective concentration, and the difference can be large for a highly bound compound.
What the structural papers add
A cryo-EM study of semaglutide- and taspoglutide-bound GLP-1R–Gs complexes reported peptide interactions similar to GLP-1 but different motions within the receptor and the bound peptides, using 3D variability analysis (reference 2). A 2026 study made G-protein-biased agonists by N-terminal modification and solved a 2.64 Å cryo-EM structure in which outward displacement of extracellular loop 3 was the key feature associated with bias; an acetylated semaglutide retained glucose-lowering activity three days after administration in diet-induced obese mice (reference 3). A 2025 study of backbone-modified analogues found prolonged signaling sensitive to the structure of the β residue at position 18, and structures of two analogues bound to the complex suggested altered peptide structure and dynamics (reference 4).
These results make one methodological point: affinity is not the only determinant of response. Two ligands with the same Ki can differ in how they pattern G-protein and β-arrestin signaling, trafficking and duration. A binding-only characterization is therefore incomplete for a study about signaling.
Designing the experiment
- Define the receptor source. Species, cell line, expression level and membrane or whole-cell format. Receptor detection itself can be method dependent (reference 7), so verify expression.
- Choose and validate the tracer. Run a saturation experiment in the same buffer to obtain Kd and Bmax.
- Use a reference ligand. A well-characterized agonist in every plate controls for plate-to-plate drift.
- Cover the full curve. At least eight concentrations, spanning at least four log units around the IC50, with duplicate or triplicate wells.
- Fit with a four-parameter model and report the Hill slope and its error.
- Convert with Cheng-Prusoff and report both IC50 and Ki with the tracer concentration and Kd.
- Add a functional readout so affinity can be set against signaling.
Preparing semaglutide for assays
Accuracy of the concentration axis determines the accuracy of everything above. The product page lists a 10 mg lyophilized powder, ≥98% HPLC purity specification, formula C187H291N45O59 and storage at 2–8 °C with −20 °C for long-term holding. Stock concentration is vial mass divided by diluent volume (C = m ÷ V); serial dilutions follow C1 × V1 = C2 × V2, and the reconstitution calculator checks the arithmetic. Because chromatographic purity is not peptide content, a protocol that depends on absolute concentration should consider quantification by amino-acid analysis or another content method; understanding HPLC purity and semaglutide purity testing explain the distinction. General aggregation and degradation concerns for peptides are reviewed in the stability literature (reference 8). Use low-binding labware, prepare dilutions fresh, and log lot numbers from the COA page.
For handling, see semaglutide reconstitution and handling; for comparators, semaglutide versus tirzepatide. The shop lists the full catalog.
Common errors to avoid
- Reporting an IC50 as an affinity. An IC50 is specific to the tracer concentration used; report Ki alongside it.
- Mixing nominal and measured concentrations. Peptide that adsorbs to plastic is lost from solution, so the true concentration at low nanomolar levels can be lower than calculated.
- Ignoring the Hill slope. A slope far from 1 suggests that a single-site competitive model does not describe the data.
- Comparing across papers. Differences in receptor source, buffer, temperature and albumin make cross-paper comparisons unreliable.
- Handling structure as function. A cryo-EM model shows one captured state; it does not by itself give kinetics or signaling output.
Reporting and interpretation
A binding result should be reported with the format, receptor species, tracer, tracer concentration and Kd, buffer including albumin, temperature, incubation time, number of independent experiments and the fitted IC50 with confidence interval. State the conversion used. Avoid statements such as "semaglutide binds more tightly than compound X" unless both were run in the same experiment, because affinity values from different laboratories depend on conditions. The 0.38 nM figure is a number from the discovery paper's own conditions and is a reference point, not a universal constant. Everything in this article is for laboratory research use only.
Frequently asked questions
What is Cheng-Prusoff?
A relationship that converts a competition-assay IC50 into an inhibition constant: Ki = IC50 ÷ (1 + [L] ÷ Kd), where [L] is the labeled-ligand concentration and Kd its dissociation constant.
What affinity did the discovery paper report for semaglutide?
0.38 ± 0.06 nM for the GLP-1 receptor, about three-fold lower than liraglutide's, with increased albumin affinity.
Why does albumin change apparent affinity?
Semaglutide binds albumin through its fatty diacid. Albumin-bound compound is not free to bind receptor, so buffer albumin changes the effective concentration.
Is binding affinity the same as potency?
No. Potency comes from functional assays and includes amplification and efficacy. Two ligands with the same Ki can differ in signaling.
What did the structural papers show?
Semaglutide-bound GLP-1R–Gs complexes showed peptide interactions similar to GLP-1 with different motions. N-terminal and backbone changes altered signaling bias and duration in other studies.
What can invalidate a Cheng-Prusoff conversion?
Non-equilibrium conditions, ligand depletion, multiple or allosteric sites and an inaccurate tracer Kd.
How is a stock concentration calculated?
Vial mass in mg divided by diluent volume in mL gives mg/mL. The site calculator converts units and checks serial dilutions.
Why consider peptide content?
HPLC purity is the fraction of chromatographic signal from the main peak, not the fraction of vial mass that is peptide. Absolute-concentration assays may need a content measurement.
How should the lyophilized vial be stored?
The product page states 2–8 °C, −20 °C for long-term holding, and protection from heat, moisture and light.
Is this article about use outside the laboratory?
No. It covers assay arithmetic and published preclinical work. Semaglutide is supplied for laboratory research use only.
Related reading: Semaglutide Half-Life Math: Pharmacokinetics vs Stability, Semaglutide and Insulin: Islet Research Readouts, Semaglutide Appetite Research: Brain Access to Circuits.
References
- Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-80. doi:10.1021/acs.jmedchem.5b00726
- Zhang X, Belousoff MJ, Liang YL, Danev R, Sexton PM, Wootten D. Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes. Cell Rep. 2021;36(2):109374. doi:10.1016/j.celrep.2021.109374
- Zhao LH, He Q, Yuan Q, Zhao GG, Wang GH, Pan HL, et al. N-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement. Cell Rep. 2026;45(7):117718. doi:10.1016/j.celrep.2026.117718
- Cary BP, Hager MV, Mariam Z, Morris RK, Belousoff MJ, Deganutti G, et al. Prolonged signaling of backbone-modified glucagon-like peptide-1 analogues with diverse receptor trafficking. Proc Natl Acad Sci U S A. 2025;122(14):e2407574122. doi:10.1073/pnas.2407574122
- Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22(23):3099-108. doi:10.1016/0006-2952(73)90196-2
- Madsen K, Knudsen LB, Agersoe H, Nielsen PF, Thøgersen H, Wilken M, et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem. 2007;50(24):6126-32. doi:10.1021/jm070861j
- McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. Endocr Rev. 2021;42(2):101-132. doi:10.1210/endrev/bnaa032
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-75. doi:10.1007/s11095-009-0045-6
